Kunming, China, October 23, 2018
Kunming Biomed International (KBI) has previously developed large cohorts of NASH and liver fibrosis models in nonhuman primates (NHPs) mirroring human patient’s disease pathophysiology, clinical progression, and histopathological stages, including steatosis monkeys (n>800), NASH monkeys (n>500) and liver fibrosis monkeys (n>150).
For the upcoming Liver Meeting® 2018 of American Association for the Study of Liver Diseases (AASLD), KBI will present its accomplishments in the development and validation of non-invasive imaging biomarkers such as PDFF and MRI-ECV as well as circulating biomarkers like TIMP-1 for the assessment of hepatic lesions in our NHP model of Nonalcoholic Steatohepatitis (NASH).
Join KBI and more than 9,500 hepatologists and hepatology health professionals from around the world at the annual AASLD conference to be held at the Moscone North and South Convention Center in San Francisco, California on 9-13 November 2018.
Our poster presentation details are below:
Publication Number: 1767
Session Date and Time: Sunday, November 11, 2018, 8:00 AM
Presentation Type: Poster Presentation
Location: Moscone Center North/South Building, Hall C
Contact us if you need more information.